Download het volledig rapport (302 p.) - KCE

KCE reports vol. 6A Prenatale zorg 131
Study Ref Population Intervention Outcomes Results Comments Study
type
Short long vs. long
RCT (n = 743): OR 1.40
long
(95% CI 0.82 to 2.38)
Shey Wiysonge
et al., 2002
European
Mode of
Delivery
4
[616]
4
[417]
1 RCT; 898 HIV-infected
pregnant women,
conducted in Kenya
Cochrane review
Most recent update 2002
436 women between 34
and 38 weeks pregnancy
with confirmed HIV-1
Nevirapine vs.
zidovudine
Nevirapine in mothers
already taking
antiretroviral therapy
vs. standard ART
Combination therapy
(zidovudine and
lamivudine) vs.
placebo
Antenatal and
intrapartum
Intrapartum and
postpartum
Vaginal disinfection
with disinfectant
(chlorhexidine) during
labour vs. no
disinfection
Caesarean section
delivery vs. vaginal
delivery
HIV infection status of
child
HIV infection status of
child by 18 months (n
= 370)
Nevirapine vs. zidovudine,
1 RCT (n = 496): OR 0.50
(95% CI 0.32 to 0.79)
Nevirapine + ART vs.
placebo + ART, 1 RCT (n =
1174): OR 1.10 (95% CI
0.42 to 2.87)
Zidovudine + lamivudine
vs. placebo, 1 RCT (n =
1792):
Antenatal and intrapartum:
RR 0.52 (95% CI 0.35 to
0.76)
Intrapartum and
postpartum: RR 0.66 (95%
CI 0.46 to 0.94)
OR 0.93 (95% CI 0.63 to
1.38)
By intention to treat:
adjusted OR 0.2 (95% CI
0.1 to 0.6)
Generation of allocation
sequence and concealment
of allocation inadequate
No woman breastfed.
Randomisation through
computer-generated lists
EL
SR 1a
RCT 1b